SGRL
Shree Ganesh Remedies financials
- Market cap
- ₹846 Cr
- Sector
- Healthcare
Quarterly results
Q1 FY27: revenue down 41.8%, net profit down 67.5% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 32 | 27 | 24 | 25 | 30 −6% | 21 −22% | 33 +36% | 14 −42% |
| EBITDA | 11 | 10 | 10 | 7 | 10 −15% | 7 −32% | 11 +15% | 3 −54% |
| Net profit | 6 | 5 | 7 | 3 | 5 −23% | 3 −43% | 6 −5% | 1 −68% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +14.0% 1Y
1Y: ₹578.05 on 10 Sept 2025 → ₹659.2. High ₹714.2 (7 Sept 2026), low ₹400.4 (27 Jan 2026).
Financials, as filed
Revenue fell 6.7% a year over 2 years, FY24 to FY26. Operating margin narrowed to 32.0%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹125 Cr | ₹109 Cr | ₹109 Cr |
| Operating profit | ₹41 Cr | ₹39 Cr | ₹35 Cr |
| Operating margin | 32.6% | 36.1% | 32.0% |
| Interest | ₹0 Cr | ₹2 Cr | ₹4 Cr |
| Depreciation | ₹6 Cr | ₹10 Cr | ₹10 Cr |
| Net profit | ₹28 Cr | ₹23 Cr | ₹18 Cr |
| Net margin | 22.7% | 21.2% | 16.3% |
| Cash from operations | ₹30 Cr | ₹31 Cr | ₹24 Cr |
| Free cash flow | ₹-1 Cr | ₹7 Cr | ₹7 Cr |
| ROCE | — | 19.0% | 14.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹10 Cr | ₹12 Cr | ₹13 Cr | ₹13 Cr | ₹13 Cr | ₹13 Cr |
| Reserves | ₹40 Cr | ₹50 Cr | ₹75 Cr | ₹109 Cr | ₹141 Cr | ₹150 Cr |
| Borrowings | ₹0 Cr | ₹0 Cr | ₹33 Cr | ₹36 Cr | ₹38 Cr | ₹31 Cr |
| Other liabilities | ₹10 Cr | ₹15 Cr | ₹18 Cr | ₹12 Cr | ₹13 Cr | ₹14 Cr |
| Total liabilities | ₹61 Cr | ₹77 Cr | ₹138 Cr | ₹171 Cr | ₹204 Cr | ₹208 Cr |
| Fixed assets | ₹19 Cr | ₹27 Cr | ₹58 Cr | ₹81 Cr | ₹105 Cr | ₹105 Cr |
| Capital work in progress | ₹2 Cr | ₹3 Cr | ₹15 Cr | ₹17 Cr | ₹9 Cr | ₹13 Cr |
| Investments | ₹3 Cr | ₹0 Cr | ₹0 Cr | ₹5 Cr | ₹19 Cr | ₹13 Cr |
| Other assets | ₹37 Cr | ₹47 Cr | ₹64 Cr | ₹69 Cr | ₹71 Cr | ₹78 Cr |
| Total assets | ₹61 Cr | ₹77 Cr | ₹138 Cr | ₹171 Cr | ₹204 Cr | ₹208 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, the public trimmed −0.55 pp while DIIs added +0.52 pp. The shareholder count shrank 15% to 7,822.
- Promoters
- 72.8%
- DIIs
- 0.5%
- Public
- 26.6%
Since Jun 2025
- Public −0.55 pp
- DIIs +0.52 pp
- Promoters +0.03 pp
How it drifted, 12 quarters
Over this window the public fell from 30.7% to 26.6% — −4.0 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 69.3%, Public 30.7%.Dec '23: Promoters 69.3%, Public 30.7%.Mar '24: Promoters 69.3%, Public 30.7%.Jun '24: Promoters 69.3%, FIIs 0.0%, Public 30.7%.Sep '24: Promoters 70.5%, FIIs 0.0%, Public 29.5%.Dec '24: Promoters 72.8%, FIIs 0.0%, Public 27.2%.Mar '25: Promoters 72.8%, FIIs 0.0%, Public 27.2%.Jun '25: Promoters 72.8%, FIIs 0.0%, Public 27.2%.Sep '25: Promoters 72.8%, FIIs 0.0%, Public 27.2%.Dec '25: Promoters 72.8%, Public 27.2%.Mar '26: Promoters 72.8%, Public 27.2%.Jun '26: Promoters 72.8%, DIIs 0.5%, Public 26.6%.
Who is on the register
Named in the Jun 2026 filing
Every holder of Shree Ganesh Remedies Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Chandulal Manubhai Kothia | 48.76% | unchanged |
| Hanshaben Chandubhai Kothia | 11.43% | unchanged |
| Pooja Gunjan Kothia | 4.79% | unchanged |
| Gunjan Chandulal Kothia | 3.21% | unchanged |
| Manubhai Jivabhai Kothiya | 1.84% | unchanged |
| Gunjan Jayantibhai Dhorajiya | 1.70% | unchanged |
| Hetvi Ketankumar Patel | 1.66% | unchanged |
| V Naga Raja Naidu | 1.27% | unchanged |
| Parth Chandulal Kothia | 1.06% | unchanged |
| Kothia Ashokkumar Manubhai (Huf) | 0.08% | unchanged |
| Vilasben Ashokkumar Kothia | 0.00% | unchanged |
| Ashokkumar Manubhai Kothia | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
Growth trapTo justify its price of ₹659, this stock must grow earnings at 34% every year for 7 years. Our analysis caps realistic growth at ~-21%. At that growth it is worth ₹35 — downside of 95%.
- Growth the price implies
- 34.4% a year
- for 7 years, fading to 4%
- It has actually compounded at
- -21.0% a year
- net profit, FY24–FY26 · EPS -21.1%
- The gap
- 0.6 pp
- -95% downside if it only repeats history
Learn to analyse Shree Ganesh Remedies Limited
Guides on how to read this kind of business and the numbers that matter.